Evidence map›Paper›PMID 25321621›Full record

Trial reportMedical science monitor : international medical journal of experimental and clinical research2014

Efficacy and safety of remifemin on peri-menopausal symptoms induced by post-operative GnRH-a therapy for endometriosis: a randomized study versus tibolone.

Jiming Chen, Hongyan Gao, Qin Li, Jing Cong, Jie Wu, Dahua Pu, Guohua Jiang

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Medical science monitor : international medical journal of experimental and clinical research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Benefits of Black Cohosh (Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  4. Article
  5. Ziyin Bushen Decoction Alleviates Perimenopausal Syndrome in Rats by Enhancing Estradiol Production.Evidence-based complementary and alternative medicine : eCAM · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jiming ChenDepartment of Obstetrics & Gynecology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China (mainland).
Hongyan GaoDepartment of Obstetrics & Gynecology, Third Affiliated Hospital of Suzhou University, Changzhou, Jiangsu, China (mainland).
Qin LiDepartment of Obstetrics & Gynecology, Third Affiliated Hospital of Suzhou University, Changzhou, Jiangsu, China (mainland).
Jing CongDepartment of Obstetrics & Gynecology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China (mainland).
Jie WuDepartment of Obstetrics and Gynecology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China (mainland).
Dahua PuDepartment of Obstetrics & Gynecology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China (mainland).
Guohua JiangDepartment of Obstetrics & Gynecology, Third Affiliated Hospital of Suzhou University, Changzhou, Jiangsu, China (mainland).
Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of this study was to investigate clinical efficacy and safety of Remifemin on peri-menopausal symptoms in endometriosis patients with a post-operative GnRH-a therapy. MATERIAL AND

methodsWe treated 116 women who had endometriosis with either Remifemin (n=56) 20 mg bid po or Tibolone (n=60) 2.5 mg qd po for 12 weeks after GnRH-a injection. The efficacy was evaluated by Kupperman menopausal index (KMI), and hot flash/sweating scores. The safety parameters such as liver and renal functions, lipid profile, endometrial thickness, and serum sex hormone level, as well as the incidence of adverse events were recorded.

results(1) After GnRH-a therapy, KMI and hot flash/sweating scores in both groups increased significantly (P<0.05) but we found no significant difference for KMI (2.87±1.40 for Remifemin and 2.70±1.26 for Tibolone) and hot flash/sweating scores (0.94±1.72 for Remifemin and 1.06±1.78 for Tibolone) between the 2 groups (P>0.05). (2) No statistical change was observed in liver or renal functions and lipid profile in both groups before and after the treatment (P>0.05). The post-therapeutic serum FSH, LH, and E2 level and endometrial thickness decreased remarkably in both groups (P<0.05). E2 level in the Remifemin group was obviously lower than that in the Tibolone group (P<0.05), and FSH and LH levels were strongly higher (P<0.05). No significant difference in thickness were found in either group (P>0.05). The Remifemin group had far fewer adverse events than the Tibolone group (P<0. 05).

conclusionsCompared with Tibolone, Remifemin had a similar clinical efficacy and was safer for the peri-menopausal symptoms induced by GnRH-a in endometriosis patients.

Indexed as

AdultCimicifugaEndometriosisFemaleGonadal Steroid HormonesGonadotropin-Releasing HormoneHumansNorpregnenesPerimenopausePlant ExtractsProspective StudiesGonadal Steroid HormonesGonadotropin-Releasing HormoneNorpregnenesPlant ExtractsRemifemintibolone

Identifiers

PMID25321621
PMCPMC4211309
OpenAlexW2164751771

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.